Entropy Technologies LP Takes Position in Illumina, Inc. (NASDAQ:ILMN)

Entropy Technologies LP bought a new stake in Illumina, Inc. (NASDAQ:ILMN) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 10,563 shares of the life sciences company’s stock, valued at approximately $1,378,000.

A number of other large investors also recently bought and sold shares of ILMN. Primecap Management Co. CA lifted its position in Illumina by 462.5% in the second quarter. Primecap Management Co. CA now owns 2,428,760 shares of the life sciences company’s stock valued at $253,514,000 after buying an additional 1,997,010 shares during the last quarter. Millennium Management LLC increased its stake in Illumina by 305.0% during the second quarter. Millennium Management LLC now owns 1,485,599 shares of the life sciences company’s stock worth $155,067,000 after purchasing an additional 1,118,747 shares during the period. Capital World Investors increased its stake in Illumina by 41.1% during the first quarter. Capital World Investors now owns 2,753,504 shares of the life sciences company’s stock worth $378,111,000 after purchasing an additional 801,814 shares during the period. Marshall Wace LLP purchased a new stake in Illumina during the second quarter worth about $77,628,000. Finally, Swedbank AB purchased a new stake in Illumina during the first quarter worth about $99,682,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Trading Down 1.0 %

Shares of ILMN stock opened at $146.17 on Thursday. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43. Illumina, Inc. has a 1 year low of $92.69 and a 1 year high of $156.66. The stock has a fifty day moving average of $138.84 and a two-hundred day moving average of $123.95. The firm has a market capitalization of $23.18 billion, a PE ratio of -14.68 and a beta of 1.13.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.26. The company had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The firm’s quarterly revenue was down 3.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.33 EPS. As a group, research analysts expect that Illumina, Inc. will post 4.11 EPS for the current year.

Analysts Set New Price Targets

A number of analysts recently weighed in on ILMN shares. Robert W. Baird upped their target price on shares of Illumina from $124.00 to $139.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 6th. Scotiabank dropped their price target on shares of Illumina from $176.00 to $164.00 and set a “sector outperform” rating on the stock in a research note on Thursday, August 15th. Daiwa America upgraded shares of Illumina to a “strong-buy” rating in a research note on Friday, August 16th. StockNews.com began coverage on shares of Illumina in a research note on Thursday, August 29th. They issued a “buy” rating on the stock. Finally, Canaccord Genuity Group increased their price target on shares of Illumina from $130.00 to $145.00 and gave the company a “hold” rating in a research note on Tuesday, November 5th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, fourteen have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $164.00.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.